How EHRA/ESC ventures into Horizon2020 funded trials. Nikos Dagres Chair of EHRA Scientific Initiatives Committee
|
|
|
- Tamsyn Wood
- 6 years ago
- Views:
Transcription
1 How EHRA/ESC ventures into Horizon2020 funded trials Nikos Dagres Chair of EHRA Scientific Initiatives Committee
2 EHRA involvement in Horizon2020 Importance Current status Obstacles Perspectives
3 EHRA involvement in Horizon2020 Importance Current status Obstacles Perspectives
4 EHRA Strategic Goals Congress Education Research Members Advocacy
5 EHRA involvement in Horizon2020 Importance Current status Obstacles Perspectives
6 Recent initiatives 1. Horizon 2020 call: ESCAPE-NET: European Sudden Cardiac Arrest network towards Prevention, Education and NEw Treatment
7 ESCAPE-NET Total budget: approx. 10 mio Euro Successful with the highest score (15 out of 15) EHRA involvement: Co-leader (together with European Resuscitation Council and P. Schwartz) in Work Package on dissemination, communication, education Current stage: Has started
8 ESCAPE-NET
9 Current projects in Horizon Horizon 2020 call: ESCAPE-NET: Sudden Cardiac Arrest Network 2. Innovative Medicines Initative 2 call: Big data in cardiovascular medicine
10 Big data in ACS, AF and HF Has received support from the EU/EFPIA Innovative Medicines Initiative [2] Joint Undertaking grant n
11 Consortium consisting of academia, pharmaceutical companies, patient networks, learned societies, SMEs It aims at delivering clinically relevant disease phenotypes, scalable insights from realworld evidence through advanced analytics, and innovative insights for driving drug development and personalised medicine. The platform comprises rich biomedical and omics-data on over 25 million subjects across Europe This work has received support from the EU/EFPIA Innovative MedicinesInitiative [2] Joint Undertaking grant n
12 EHRA involvement
13 Current projects in Horizon Horizon 2020 call: ESCAPE-NET: Sudden Cardiac Arrest Network 2. Innovative Medicines Initative 2 call: Big data in cardiovascular medicine 3. Horizon 2020: CATCH ME
14 CATCH ME Aims: improve the prevention and treatment of Atrial Fibrillation Develop and validate better disease management strategies based on the improved understanding of the main health modifiers Identify the major health modifiers causing AF Develop clinical tools to personalise the AF patients management Guide and strengthen future strategies to prevent, diagnose, and treat AF More info: Receiving funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement no
15 Current projects in Horizon Horizon 2020 call: ESCAPE-NET: Sudden Cardiac Arrest Network 2. Innovative Medicines Initative 2 call: Big data in cardiovascular medicine 3. Horizon 2020: CATCH ME 4. Horizon 2020 call: RESET SCD Trial
16 An EHRA Initiative REevaluation of optimal treatment Strategies for prevention of Sudden Cardiac Death in patients with ischemic cardiomyopathy RESET SCD International Chief Investigator: G. Hindricks
17 RESET SCD - Background Main guideline relevant trials years old MADIT II Trial begin July 1997, published 2002 Since then significant changes in therapy reducing mortality: New drugs, e.g. eplerenone, ARNI Wider beta blocker use (MADIT II baseline 60%, last follow up 72%) and statin use Improved revascularization strategies
18 RESET SCD Trial design Patients with ischemic cardiomyopathy eligible for ICD indication for primary prevention Randomization: ICD vs optimal medical treatment Sample size: patients
19 Horizon2020 application for RESET SCD Two-stage application Successful in the first stage (10%, threshold 9.5 of 10) Preparing the full application Deadline: April 2017
20 EHRA involvement in Horizon2020 Importance Current status Obstacles Perspectives
21 Complex structure
22 Very competitive
23 EHRA involvement in Horizon2020 Important! Opportunities for funding big, relevant projects Difficult, but doable
Horizon Introduction. Alex Harris Medical Research Council
Horizon 2020 - Introduction Alex Harris Medical Research Council Agenda MRC and Horizon 2020 UK Success Rate (FP7 Health) What is Horizon 2020? The Horizon 2020 Health Challenge NCP support MRC and Horizon
14 December :00 CET
Webinar IMI2 Call 13 Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches 14 December 2017 15:00 CET Agenda How to use
Device detected AF and atrial high rate episodes
Device detected AF and atrial high rate episodes Professor Paulus Kirchhof University of Birmingham Institute of Cardiovascular Sciences SWBH and UHB NHS trusts, Birmingham, UK Department of Cardiovascular
Update from IMI PREFER: Patient preferences in benefitrisk assessments during the medical product lifecycle
1 1 Update from IMI PREFER: Patient preferences in benefitrisk assessments during the medical product lifecycle Presenter: Chiara Whichello on behalf of the PREFER consortium June 5, 2018 The statements
Risk prediction in inherited conditions Laminopathies
Risk prediction in inherited conditions Laminopathies Karim Wahbi Cochin hospital, Paris karim.wahbi@aphp.fr Risk prediction in laminopathies Current approach for risk stratification A new score to predict
Gesundheit in Horizont 2020
Wien, 5, Dezember 2013 Gesundheit in Horizont 2020 Gesellschaftliche Herausforderung 1: Gesundheit, demografischer Wandel und Wohlergehen Dr Elmar Nimmesgern GD Forschung und Innovation Europäische Kommission
Silvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
What EU research policy can do for conditions such as chronic pain?
The EU Framework Programme for Research and Innovation HORIZON 2020 What EU research policy can do for conditions such as chronic pain? K Berkouk, PhD Deputy Head of Unit, Non-communicable diseases and
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
New Horizons for Vaccine R&D&I in Europe
New Horizons for Vaccine R&D&I in Europe Health, Demographic Change and Wellbeing Ruxandra Draghia-Akli MD, PhD Directorate E - Health Research DG - Research & Innovation European Commission Why EU support
Regional program of the East Europe and Central Asia Union of PLWH within the framework of the Global Fund New Funding Model
Regional program of the East Europe and Central Asia Union of PLWH within the framework of the Global Fund New Funding Model Background for the program development Problem areas Access to the whole HIV-care
The European Framework Program for Research & Innovation: Horizon 2020: Health, demographic change & wellbeing
The European Framework Program for Research & Innovation: Horizon 2020: Health, demographic change & wellbeing Sasha Hugentobler National Contact Point Health Euresearch Head Office phone +41 31 380 60
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In?
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor of Medicine Director,
You will have responsibility for:
Public Engagement Officer UKRI NERC BGS Lyell Centre, Edinburgh 30,357-32,997 (depending on qualifications and experience) Full Time 37 hours a week (a range of flexible working options may be available)
Prognostic Importance of Defibrillator Shock
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/prognostic-importance-of-defibrillator-shock/3680/
Global Action Against Dementia: Finding a Path Forward and the World Dementia Council
Global Action Against Dementia: Finding a Path Forward and the World Dementia Council Raj Long MBPsS MSc Vice Chair World Dementia Council ASAD Hangzhou October 2016 1 Overview 1. Global State of Dementia
Sudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
Horizon Tailored screening as a research challenge. Mireille Broeders 30 January 2014, Bologna
Horizon 2020 Tailored screening as a research challenge Mireille Broeders 30 January 2014, Bologna Dept for Health Evidence, Radboudumc & National Expert and Training Centre for Breast Cancer Screening,
Moving towards 2020 priorities for Public Health for the years Health and Consumers
Moving towards 2020 priorities for Public Health for the years 2013-20 Health in the MFF 2014-2020 Commission proposal for the Health for Growth Programme 2014-2020 http://ec.europa.eu/health/programme/policy/index_en.htm
EU funding of animal health research
EU funding of animal health research Jean-Charles CAVITTE Research Policy Officer Research and Innovation Unit European Commission DG Agriculture and Rural Development The presentation shall neither be
ITCC-P4 International Workshop
ITCC P4 GA No. 116064 ITCC-P4 International Workshop IMPROVING PEDIATRIC ONCOLOGY DRUG DEVELOPMENT THROUGH PRECLINICAL RESEARCH September 27 th and 28 th, 2018 // Amsterdam, NL By invitation The event
Counting down to zero
12%... 10%... 8%... Counting down to zero Towards a future with underfunded health research? We, as representatives of the undersigned organisations, welcome the current European Commission s proposal
NORDIC CONFERENCE ON RARE DISEASES
www.eurordis.org NORDIC CONFERENCE ON RARE DISEASES 31 May 2012, Reykjavik, Iceland www.eurordis.org RARE DISEASES IN EUROPE Terkel ANDERSEN President of EURORDIS European Organisation for Rare Diseases
Towards tailored and targeted asthma self-management using mobile technologies
Towards tailored and targeted asthma self-management using mobile technologies Funded by the European Union Asthma: the problem Asthma is a lifelong chronic disease caused by inflammation of the airways,
Gender Aspects in R&I Horizon Stephanie Rammel Gender Expert in H2020 and ERA FFG - Austrian Research Promotion Agency
Gender Aspects in R&I Horizon 2020 Stephanie Rammel Gender Expert in H2020 and ERA FFG - Austrian Research Promotion Agency This presentation is about Horizon 2020: where are gender aspects relevant for
Heart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
Spreading Excellence and Widening Participation
Spreading Excellence and Widening Participation Dr G Ambroziewicz Ankara, 27/02/2017 Research and Background Disparities in research and innovation performance: barrier to competitiveness, growth and jobs
Risk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
INSIGHTS INTO ADHD CARE IN GERMANY BASED ON SHI CLAIMS DATA 03. March Results of the CoCA Study (Horizon 2020)
03. March 2017 INSIGHTS INTO ADHD CARE IN GERMANY BASED ON SHI CLAIMS DATA Results of the CoCA Study (Horizon 2020) Who are we? HGC looks back on close to 30 years of experience in the health care sector
Enhancing the Quality of Heart Failure Care
Enhancing the Quality of Heart Failure Care 2 Enhancing the quality of Heart Failure care Contents 2 Heart failure care in the UK: Case for change Heart failure in the UK: Case for change Heart failure
DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
Enhancing the Quality of Heart Failure Care
Enhancing the Quality of Heart Failure Care 2 Enhancing the quality of Heart Failure care Kent Surrey Sussex Academic Health Science Network 3 Contents 2 Heart failure care in the UK: Case for change 3
Guideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
Alcohol Research UK Research Strategy
Alcohol Research UK Research Strategy 2015-18 Supporting research to reduce alcohol-related harm www.alcoholresearchuk.org Alcohol Research UK Research Strategy 2015-18 Foreword Professor Alan-Maryon Davies
PCHF A NOVEL COURSE IN HEART FAILURE MANAGEMENT POSTGRADUATE COURSE IN HEART FAILURE LONDON. January 2019 to October 2020
PCHF POSTGRADUATE COURSE IN HEART FAILURE LONDON A NOVEL COURSE IN HEART FAILURE MANAGEMENT January 2019 to October 2020 Venue: The Royal Society of Medicine, 1 Wimpole Street, Marylebone, London, UK Endorsed
Abbreviation List: 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation. 1
2017 AHA/ACC/HRS Systematic Review for the Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Data Supplement Table of Contents Part 1. For Asymptomatic
Heart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
Testimony of a failed reimbursement change: why it went wrong Device implantation in Sweden
Testimony of a failed reimbursement change: why it went wrong Device implantation in Sweden Frieder Braunschweig MD PhD FESC FACC Professor of Cardiology, Director of Arrhythmia Heart and Vascular Theme
IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM
IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM Dr Anke M Schulte, Head of Islet Biology Department Sanofi-Diabetes Frankfurt, Germany 11th of July, 2014 General
New scientific documents from EHRA Management of patients with defibrillator shocks
New scientific documents from EHRA Management of patients with defibrillator shocks Frieder Braunschweig MD PhD FESC Karolinska University Hospital Stockholm, Sweden Evolution of ICD therapy Worldwide
Dr.sc. Branka Bernard National Contact Point Member of the Programme Committee
Horizon 2020 - societal challenge 1 Health, demographic change and wellbeing Work Programme 2014-2015 Dr.sc. Branka Bernard National Contact Point Member of the Programme Committee HORIZON 2020 Work Programmes
NEWSLETTER Partners. 43 Months WPs Deliverables. 8 Use Cases Companies RTDs. Contents. Keywords
Welcome to the first issue of the OActive Newsletter! NEWSLETTER Issue 1: December 2018 Contents 1. OActive at a glance 2. OActive website, video & milestones 3. OActive Physical Meetings 4. Attendance
HIV, Sexual and Reproductive Health and Rights (SRHR), Nutrition and Gender: Capacity-building in partnership with Canadian organizations
HIV, Sexual and Reproductive Health and Rights (SRHR), Nutrition and Gender: Capacity-building in partnership with Canadian organizations Call for Expressions of Interest from Community-Based Organizations
Cancer Research in the EU Framework Programmes for RTD
Cancer Research in the EU Framework Programmes for RTD Action against cancer: European platform Maria Vidal, MD, PhD Deputy Head of Unit Medical and public health research Health Directorate DG Research
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
ESC CONGRESS HIGHLIGHTS ARRHYTHMIAS. M. Bertini (Ferrara, IT) Conflicts of Interest none
ESC CONGRESS HIGHLIGHTS ARRHYTHMIAS M. Bertini (Ferrara, IT) Conflicts of Interest none Data that may change daily practice... Atrial fibrillation OACs in real life - BEYOND program Halvorsen S 2951 OAC
8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)
Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor
From IMI to IMI2. Hugh Laverty Senior Scientific Project Manager
From IMI to IMI2 Hugh Laverty Senior Scientific Project Manager FitForHealth June 2014 Innovative Medicines Initiative: Joining forces in the healthcare sector The biggest public/private partnership in
Cardiac Resynchronization ICD Therapy: What is New?
Cardiac Resynchronization ICD Therapy: What is New? Emile Daoud, MD Section Chief, Cardiac Electrophysiology Professor of Medicine The Ohio State University Normal Activation, Narrow QRS Synchrony Abnormal
Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
Toolkit to Establish an Arrhythmia Alliance National Partner
Toolkit to Establish an Arrhythmia Alliance National Partner +44 (0) 1789 450787 trudie@heartrhythmcharity.org.uk Index 2 1. Introduction..3 2. National Partners and Affiliates..4 3. The 8 Steps to Start
Sudden cardiac death: Primary and secondary prevention
Sudden cardiac death: Primary and secondary prevention By Kai Chi Chan Penultimate Year Medical Student St George s University of London at UNic Sheba Medical Centre Definition Sudden cardiac arrest (SCA)
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
Consolidated plan for the Centre for Global Health
Consolidated plan for the Centre for Global Health Presentation to the Faculty of Medicine Board 8 May, 2018 AS Winkler Centre for Global Health 1 Mission The mission of the CGH is to facilitate high quality
CRT Vs RV Pacing Benefits
CRT-P & CRT-D Indications According to Guidelines are Guidelines Fully Adopted? Salama H. Omar M.D. Prof. Critical Care Medicine, Cairo University CRT Vs RV Pacing Benefits 1 Benefit of Upgrade CTR-P &
Remote Assessment of Disease and Relapse Central Nervous System-RADAR-CNS
VOLUME 5 NO 4, 2017 Remote Assessment of Disease and Relapse Central Nervous System-RADAR-CNS J.M. Garzón-Rey and J. Aguilo Department of Microelectronics and Electronic Systems, Universidad Autónoma de
Marie Skłodowska-Curie Actions (MSCA) Individual Fellowships (IF) for participants from Japan European Research Council (ERC)
Marie Skłodowska-Curie Actions (MSCA) Individual Fellowships (IF) for participants from Japan European Research Council (ERC) Matthieu Py, EURAXESS Japan EURAXESS Japan Tour @NagoyaU, 25 July 2017 Japan
Sudden Cardiac Death
Sudden Cardiac Death management challenges of a global problem Zayd A. Eldadah, MD, PhD Co-Director, Cardiac Electrophysiology, Washington Hospital Center Director, Cardiac Electrophysiology, Georgetown
Job information pack Interim Head of Strategic Marketing
Job information pack Interim Head of Strategic Marketing Thank you for your interest in Pancreatic Cancer UK It is a pleasure to know that you are interested in working with us. Please find enclosed further
Brain research supported by the European Union
Brain research supported by the European Union Lara Passante, PhD Health Directorate Directorate-General for Research & European Commission FENS Featured Regional Meeting 11-14 Septembre 2013 Prague Neuroscience:
Predictive Diagnosis. Clustering to Better Predict Heart Attacks x The Analytics Edge
Predictive Diagnosis Clustering to Better Predict Heart Attacks 15.071x The Analytics Edge Heart Attacks Heart attack is a common complication of coronary heart disease resulting from the interruption
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research
E-RARE & THE EUROPEAN JOINT PROGRAMME ON RARE DISEASES. RE(ACT) 2018 Congress 7-10 of March 2018 Bologna, ITALY
E-RARE & THE EUROPEAN JOINT PROGRAMME ON RARE DISEASES RE(ACT) 2018 Congress 7-10 of March 2018 Bologna, ITALY E-RARE THE ERA-NET FOR RESEARCH PROGRAMMES ON RARE DISEASES MAJOR FACTS ABOUT E-RARE ERA-NET
Practice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare?
1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare? Dr Nerys Davies, GPST Ms B. Davies, Specialist Nurse (Heart Failure) Dr J. Taylor, Consultant Cardiologist
Table Of Content. Annex 1: Conference report... 7 Annual project reports (URL)... 7 Original Full Information (Dec 2008)... 7.
Table Of Content Alcohol Policy Network in the Context of a Larger Europe: Bridging the Gap... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 Annex 1: Conference report... 7
Sudden Cardiac Death and Asians Disclosures
Sudden Cardiac Death and Asians Disclosures 7 February 2009 Asian Heart and Vascular Symposium None Zian H. Tseng, M.D., M.A.S. Assistant Professor of Medicine Cardiac Electrophysiology Section University
Towards a coordinated risk assessment framework?
Towards a coordinated risk assessment framework? Zsuzsanna Jakab, ECDC Director 3 rd meeting of the Chairs of the Scientific Committees and Panels Stockholm, 6-7 November 2007 ecdc.europa.eu Content of
INTERNATIONAL INITIATIVE FOR ACTION AND RESEARCH ON TOBACCO
INTERNATIONAL INITIATIVE FOR ACTION AND RESEARCH ON TOBACCO Opportunities for collaboration with low- and middle-income countries Alison Cox, Director for Cancer Prevention, CRUK 19 th July, 2014 ASH Scotland
Isabelle Schwartz-Cornil, coordinator. Marie-Hélène Pinard-van der Laan, deputy coordinator
Isabelle Schwartz-Cornil, coordinator Marie-Hélène Pinard-van der Laan, deputy coordinator Manchester, 5-6 January 2016 WORK PROGRAMME 2014-2015 Food security, sustainable agriculture and forestry, marine
D.Soc.Sc., Developmentleader at the Itla foundation Petra Kouvonen, Finland
Turning evidence -based (EB) knowledge on the issues of supporting the early years of children s lives into policymaking and practice issues to be considered D.Soc.Sc., Developmentleader at the Itla foundation
Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
Implications for public health research. Professor Bernie Hannigan Director - Research, Translation & Innovation
Implications for public health research Professor Bernie Hannigan Director - Research, Translation & Innovation Our mission To protect and improve the nation s health and to address inequalities...working
Press Release. Page 1 of 6
Press Release Daiichi Sankyo Presents Positive Results of the First Randomized, Controlled Trial of Uninterrupted Oral, Once-daily Lixiana (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter
Quality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
An overview of EU funding for Brain and Related Diseases. Aldo Tagliabue
An overview of EU funding for Brain and Related Diseases Aldo Tagliabue FP7 2007-2013 50.5 Billion for the Specific Programmes JRC Euratom 1.947 Cooperation 1.751 32.365 Capacities 4.217 People 4.728 Ideas
Jūratė Švarcaitė Pharmaceutical care programmes manager, Nemuno vaistinė
Forum for innovators: Pharmaceutical services implementation Successes and outcomes case study from Lithuania Title: 74 th FIP World Congress of Pharmacy and Pharmaceutical Sciences Chairs: Jūratė Švarcaitė
EU Funding for Global Health Research and Development (GH R&D) Cecile Vernant, Head of EU Advocacy, DSW EU 13 June 2014
EU Funding for Global Health Research and Development (GH R&D) Cecile Vernant, Head of EU Advocacy, DSW EU 13 June 2014 EU Horizon 2020 for 2014-2020 In current prices nearly 80 billion; in constant prices
Chapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
Future of diabetes research in the EU- the EC perspectives
Future of diabetes research in the EU- the EC perspectives Dr Karim Berkouk, Deputy Head of Unit DG for Health Directorate European Commission Overview Challenges in diabetes Research in diabetes at EU
Eurasian Harm Reduction Association (EHRA) Strategic Framework
Eurasian Harm Reduction Association (EHRA) Strategic Framework 2018-2019 What is Eurasian Harm Reduction Association (EHRA)? 2 How does strategic framework work? 2 Harm reduction, current context 3 EHRA
Achievements
Celebrating our Achievements 1999-2014 Executive summary www.canadianstrokenetwork.ca Celebrating our Achievements Canadian Stroke Network 1999-2014 Our mission was to reduce the impact of stroke on Canadians
Chapter 8: Cardiovascular Disease in Patients with ESRD
Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)
Article 1: MEDSTARTUP
Article 1: MEDSTARTUP MedStartUp is a GALIEN FOUNDATION BUSINESS FRANCE program initiative which aim to allow, encourage and reward new international partnerships between innovative French and North American
Heart Failure Challenges and Unmet needs
Heart Failure Challenges and Unmet needs. Angelo Auricchio, MD FESC Director, Cardiac Electrophysiology Programme, Fondazione Cardiocentro Ticino, Lugano, Switzerland Professor of Cardiology, University
European Patients Academy on Therapeutic Innovation
European Patients Academy on Therapeutic Innovation http://www.patientsacademy.eu info@patientsacademy.eu The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under
Polypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
Chapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
Sponsorship Opportunities
Sponsorship Opportunities Contents Page Introduction 3 About One Nucleus 3 Why Sponsor One Nucleus? 4 Sponsorship Benefits 4 Corporate Sponsorship 5 Event Sponsorship 6 - Network Meetings and BioWednesdays
Preventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
What Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
GAVI, THE VACCINE ALLIANCE
#vaccineswork GAVI, THE VACCINE ALLIANCE Partnerships for Health Outcomes Susan Brown July, 2017, New York Gavi/2012/Doune Porter www.gavi.org 1 ABOUT GAVI Gavi s mission: to save children s lives and
Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK
Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK 1. Introduction 1.1. Alzheimer s Research UK is the UK s leading dementia research charity. As research experts,
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
Health related issues in Moldova. Stanislav Groppa, MD, PhD, Prof., Acad. Victor Vovc, MD, PhD, Prof.
Health related issues in Moldova Stanislav Groppa, MD, PhD, Prof., Acad. Victor Vovc, MD, PhD, Prof. Health Research institutions network of the Republic of Moldova SUMPh Nicolae Testemitanu Mother and
Sponsorship opportunities 2018
Sponsorship opportunities 2018 11-13 September 2018 Edingburgh Assembly Rooms 54 George Street Edinburgh EH2 2LR Winners announced: 13 September 2018 Sheraton Grand Hotel Edinburgh About the annual seminar
DRUG DISCOVERY INSIGHTS EVOTEC AND BAYER ALLIANCE TO FIGHT CHRONIC COUGH
DDin DRUG DISCOVERY INSIGHTS EVOTEC AND BAYER ALLIANCE TO FIGHT CHRONIC COUGH Endometriosis alliance expanded into new field with high unmet medical need THE EVOTEC - BAYER COLLABORATION Background In